Gan & Lee Pharmaceutical

About:

Gan & Lee pharmaceutical is a Chinese high-tech biopharmaceutical company engaged in the R&D of insulin glargine and insulin lispro.

Website: http://www.ganlee.com

Twitter/X: ganlee_

Top Investors: Qiming Venture Partners, Goldman Sachs, Hillhouse Investment, Tengye Ventures

Description:

Founded in 1998, Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China. Since its inauguration, Gan & Lee has been focusing on insulin production. In 1998, Gan & Lee successfully developed the first domestic biosynthetic human insulin, which was evaluated as China’s top 10 scientific and technological breakthroughs by Chinese Academy of Sciences and Engineering. Hitherto Gan & Lee has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin®, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25®, all of which have received high reputation from nationwide clinicians and patients, with outstanding efficacy and safety guarantees.